Balancing pipeline investment across therapeutic areas — and platforms — to avoid concentration risk from a single scientific bet
Before a pipeline can be judged "diversified" or "concentrated," every asset must be consistently tagged by therapeutic area (TA) and weighted by a comparable measure of value — not simply counted. A six-asset oncology-only pipeline and a six-asset pipeline spread across oncology, immunology, and rare disease look identical by headcount but carry very different risk profiles, and the difference only becomes visible once assets are plotted as a share of total portfolio value rather than as a share of total asset count.
A pipeline is a portfolio of options, and options are worth very different amounts depending on their stage, their probability of technical and regulatory success, and the size of the market they address if they succeed. Risk-adjusted net present value (rNPV) — the standard portfolio-valuation method in biopharma — discounts each asset's peak-sales potential by its stage-specific probability of success and the time value of money, producing a single comparable value figure per asset regardless of therapeutic area or modality.
When a portfolio is mapped by rNPV-weighted TA share rather than by simple asset count, the picture often changes dramatically. A single Phase 3 oncology asset with a large addressable market and a high late-stage probability of success can represent more portfolio value than five preclinical rare-disease programs combined. Reporting "we have assets in six therapeutic areas" without disclosing the value-weighted distribution across them is a common way concentration risk goes unnoticed by boards and investors alike — the label diversity masks a value concentration that a simple count-based summary cannot reveal.
The TA categories themselves require a deliberate, consistently applied taxonomy. Overly broad buckets (e.g., a single "Immunology" category spanning autoimmune disease, transplant rejection, and allergic disease) can hide real diversification; overly narrow buckets (splitting oncology into a dozen tumor-type sub-categories) can manufacture an illusion of diversification that does not reflect genuine differences in underlying biology, competitive dynamics, or regulatory pathway.
Most portfolio-management functions settle on 5–8 top-level TA buckets aligned to how the organization is commercially and scientifically organized — Oncology, Immunology, Neurology, Rare Disease, Cardiometabolic, and Infectious Disease is a common structure — and hold that taxonomy stable across review cycles so that TA-share trends can be tracked meaningfully over time rather than re-derived from scratch at every board meeting.
The single most important discipline in TA mapping is holding the taxonomy and the value-weighting method constant across review cycles — a portfolio that looks "more diversified" quarter over quarter only because the TA buckets were redrawn is not actually less concentrated; it has simply been re-labeled.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Oncology | |||
| Immunology | |||
| Neurology | |||
| Rare Disease | |||
| Cardiometabolic | |||
| Infectious Disease |
A donut chart of TA shares is useful for a visual gut check, but it does not produce a single, comparable number that can be tracked over time or benchmarked against a threshold. The Herfindahl-Hirschman Index (HHI) — the standard measure antitrust regulators use to assess market concentration in a merger review — provides exactly that: a single scalar computed by summing the squares of each participant's share, applied here to a portfolio's TA allocation instead of a market's competitor shares.
A naive concentration metric might simply report the largest single TA's share of portfolio value. HHI improves on this by squaring every participant's share before summing, which means it is sensitive not just to the single largest TA but to the entire shape of the distribution. Two portfolios can have an identical 40% largest-TA share, but one where the remaining 60% is split evenly across five other TAs is meaningfully less concentrated — and will score a meaningfully lower HHI — than one where the remaining 60% is split between just one other TA.
The squaring operation disproportionately penalizes large shares: a TA at 50% contributes 0.25 to the index, four times as much as a TA at 25% (which contributes 0.0625), even though the first is only twice the size of the second. This convexity is a deliberate design feature, not an artifact — it reflects the intuition that risk from concentration grows faster than linearly as a single bet gets larger.
The Department of Justice and FTC Horizontal Merger Guidelines treat a market as "unconcentrated" below an HHI of 0.15 (1,500 on the conventional 0–10,000 scale used in antitrust practice), "moderately concentrated" between 0.15 and 0.25, and "highly concentrated" above 0.25. Applied to a therapeutic-area allocation, these same thresholds provide a borrowed but genuinely useful benchmark: a portfolio with an HHI above roughly 0.25–0.30 is carrying meaningful concentration risk from a single scientific or clinical setback in its dominant TA, in much the same way a market with few competitors is vulnerable to the failure or misconduct of any one of them.
The analogy is imperfect and worth stating plainly: antitrust HHI measures anticompetitive market power, not technical or clinical risk. A biopharma portfolio HHI measures value concentration, not the probability that any given TA's assets will fail. The two concepts are related — concentrated exposure amplifies the consequence of a low-probability failure — but HHI alone says nothing about how likely that failure actually is, which is precisely the gap that platform and target correlation analysis (Stage 3) exists to fill.
A portfolio HHI of roughly 0.15–0.20 is a reasonable target range for organizations that want genuine risk diversification without diluting scientific focus into an unmanageable number of small, thinly resourced programs — below that range, coordination and expertise costs typically start to outweigh the incremental risk-reduction benefit.
HHI is a static snapshot of value distribution across labeled categories at a point in time. It says nothing about the trajectory of that distribution (is concentration increasing or decreasing deal by deal), nothing about the quality or defensibility of the assets within each TA, and — most importantly for a science-driven organization — nothing about correlation risk that cuts across the TA labels entirely. Two portfolios with identical HHI scores can carry very different real-world risk if one is diversified by TA label but concentrated on a single delivery platform, while the other is genuinely diversified across both TA and underlying mechanism.
Therapeutic-area diversification is necessary but not sufficient. A portfolio can score a healthy HHI on TA labels while still being dangerously concentrated on the underlying science: the same delivery platform, the same target class, or the same mechanism of action can run underneath assets that are formally tagged as belonging to entirely different therapeutic areas — and a class-wide failure in that shared science can take out several "diversified" assets in a single event.
Consider an illustrative portfolio with assets formally tagged across oncology, rare disease, and neurology — a TA allocation that would score comfortably in the "moderately concentrated" or even "unconcentrated" HHI range. If three of those assets, one in each labeled TA, are built on the same adeno-associated virus (AAV) capsid serotype for gene-therapy delivery, they share a specific correlated risk that the TA labels do not capture at all: a capsid-associated immunogenicity finding, a manufacturing contamination issue at the shared vector-production facility, or a regulatory class hold on that capsid family could simultaneously impair all three assets regardless of how different their target diseases are.
The same logic applies to shared target classes (multiple assets built around the same receptor or signaling pathway, vulnerable to a single class-wide mechanistic safety signal), shared modalities (multiple bispecific antibodies vulnerable to a shared cytokine-release-syndrome liability), and shared external dependencies (multiple programs reliant on the same contract manufacturing organization or the same licensed core technology). None of these correlations show up in a TA-share donut chart; all of them show up in a platform map.
A correlation map requires tagging every asset a second time, orthogonally to its TA label, by its underlying scientific dependencies: delivery platform (e.g., lipid nanoparticle formulation, AAV serotype, viral vector backbone), target or pathway (e.g., a specific cytokine, receptor, or enzyme), and modality/mechanism class (e.g., bispecific antibody, antisense oligonucleotide, CAR-T). Assets sharing two or more of these tags are flagged as materially correlated — not merely thematically similar.
The output is typically visualized as a network or matrix layered on top of the TA donut: threads connecting correlated assets across TA boundaries, with the density of connections at any one node indicating how much of the portfolio's risk-bearing capacity rests on that single piece of shared science. A portfolio review that only ever produces a TA-share chart will systematically underweight this risk, because correlation by construction is invisible to any single-axis categorization.
The right mental model is that TA diversification and platform diversification are two separate, only loosely correlated dimensions of portfolio risk — a genuinely resilient pipeline needs an acceptable HHI on both axes independently, not just on the one that happens to be reported on the cover slide of the portfolio review.
Once concentration risk is quantified on both the TA and platform axes, portfolio leadership faces a genuine strategic choice, not a mechanical one. There is no universally correct HHI target; the right response depends on the organization's scientific differentiation, its capital position, and a candid judgment about whether its concentration reflects unmanaged risk or a deliberate, well-reasoned bet on deep expertise.
The most direct lever for reducing concentration is bringing in an asset, platform, or company in an under-represented TA through in-licensing, an asset acquisition, or a company acquisition. This is typically the fastest way to move the HHI needle in a single transaction, but it is also the most expensive and carries its own integration and diligence risk: an acquired asset in a genuinely novel-to-the-organization TA may lack the internal expertise needed to develop it well, effectively trading concentration risk for execution risk.
Well-run business-development functions maintain a standing "TA gap" list derived directly from the portfolio HHI analysis, so that when an attractive external opportunity in an under-represented area surfaces, it can be evaluated partly on its stand-alone merits and partly on its portfolio-level diversification value — a discipline that prevents BD from drifting toward whatever deals are simply available rather than the areas the portfolio actually needs.
The mirror-image lever is reducing exposure to an over-represented TA through out-licensing, spinning out a subset of assets, or simply deprioritizing internal investment in favor of external partners. Divestment is often underused relative to acquisition because it can read internally as an admission of past overinvestment, but a disciplined portfolio process treats trimming an over-concentrated TA as no different in principle from adding to an under-represented one — both are HHI-improving moves, and divestment has the added benefit of frequently generating non-dilutive capital (upfronts, milestones, royalties) that can fund the acquisition side of the rebalancing.
It is a mistake to treat every elevated HHI as a problem to be solved. Some of the most successful biopharma companies in history have been built on deliberate, sustained concentration in a single therapeutic area or platform, on the theory that deep, compounding expertise in one domain — better target selection, faster trial execution, a stronger KOL network, a more efficient regulatory relationship with a single review division — produces a higher probability of success per dollar invested than the same capital spread thinly across unfamiliar areas. This is the biopharma analogue of a concentrated, high-conviction investment strategy versus an index-fund approach: lower diversification, but potentially higher risk-adjusted return if the underlying expertise edge is real.
The distinction that matters is not concentrated versus diversified in the abstract, but managed versus unmanaged concentration. A portfolio committee that reviews its HHI, explicitly documents why it is choosing to remain concentrated (citing a specific, defensible scientific or commercial edge), and revisits that decision on a fixed cadence is practicing deliberate concentration. A portfolio that arrived at the same HHI through a sequence of individually reasonable deal decisions, with no one ever stepping back to compute the aggregate exposure, is practicing unmanaged concentration — and is carrying the same risk without having made the same conscious trade-off.
A portfolio committee should be able to answer, for any TA or platform above roughly a 30% value share, a simple question: "if this were wiped out tomorrow by a single class-wide event, would we say we chose that risk, or would we say we drifted into it?" Only the first answer reflects a defensible strategy.
The clearest way to make concentration risk concrete is to simulate what actually happens to portfolio value when the correlated failure scenario from Stage 3 occurs. A simplified stress test — not a precise financial model, but an illustrative comparison — shows why two portfolios with superficially similar asset counts can experience very different outcomes when a single platform-wide event strikes their largest shared exposure.
The simulation shown here deliberately simplifies a real risk-adjusted return analysis to isolate one mechanism: when a platform-wide failure event strikes, the portfolio-level value loss is approximately proportional to the value share concentrated in the affected slice, not to the total number of therapeutic areas the portfolio nominally spans. A six-TA portfolio whose largest single TA still carries a modest value share absorbs a shock to that TA as a modest, survivable loss. A three-TA portfolio whose largest TA carries a much larger value share absorbs the same category of shock as a much larger, potentially strategy-altering loss.
This is the direct, intuitive translation of the HHI concept from Stage 2 into an outcome: HHI is, in effect, a forward-looking estimate of exactly this kind of expected single-event loss, expressed as a unitless index rather than a dollar figure. A rigorous version of this exercise would run a full Monte Carlo simulation across many possible failure scenarios, each with its own probability and its own affected asset set, and would report a full distribution of possible portfolio outcomes rather than a single illustrative shock — the simplified two-donut comparison here is meant to build correct intuition for that fuller analysis, not to replace it.
The simulation should not be read as an argument that diversification is always the correct choice. A genuinely diversified portfolio also gives up the expected-return benefits of deep specialization discussed in Stage 4 — spreading capital and attention across more TAs and platforms typically means each individual bet receives fewer resources and a shallower pool of internal expertise, which can lower the probability of success for every asset in the portfolio simultaneously, a cost the stress test does not capture because it only models the downside of a correlated failure, not the upside of expertise concentration.
The honest conclusion is a portfolio-theory one, familiar from financial markets: diversification reduces the variance of outcomes and protects against a single catastrophic loss, at some cost to expected return if the concentrated alternative would otherwise have benefited from genuine execution advantages. The right portfolio strategy is the one that consciously chooses a point on that risk-return frontier — using the HHI and correlation-mapping tools from Stages 2 and 3 to know exactly where the portfolio currently sits — rather than the one that arrives at either extreme by accident.
The purpose of quantifying concentration risk is not to force every portfolio toward the same HHI target. It is to ensure that wherever a portfolio sits on the diversified-to-concentrated spectrum, it sits there by an informed, revisited decision rather than by the unexamined accumulation of individually reasonable deals.